Use of nonmyeloablative preparative regimens for allogeneic blood stem cell transplantation: Induction of graft-vs.-malignancy as treatment for malignant diseases

Champlin, Richard E.; Khouri, Issa F.; Giralt, Sergío

doi:10.1002/(sici)1098-1101(1999)14:1<45::aid-jca9>3.0.co;2-r

Cited by 7 publications

(2 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Actuarial probability of disease-free survival at 14 months is reported as 77.5% [52••]. This topic has been recently reviewed, and, if the preliminary reports are confirmed, it may revolutionize the field of allograft, requiring reassessment of who should be a candidate for stem-cell transplant [53].…”

Section: Future Directionsmentioning

confidence: 99%

Therapy for childhood acute myeloid leukemia: Role of allogeneic bone marrow transplantation

Abella

Ravindranath

2000

Curr Oncol Rep

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) has one of the lowest survival rates of childhood cancers. The first significant improvement in AML therapy started with the introduction of the now standard regimen of 3 days of anthracyclines and 7 days of cytarabine (Ara-C), the so-called 3+7 combinations. Several different therapeutic approaches have been taken in attempts to improve the outcome, including intensification of therapy both for remission induction and in the postremission phase. Intensification of postremission therapy included multiple courses of high-dose chemotherapy and/or myeloablative therapy followed by stem- cell rescue from either allogeneic or autologous sources. Furthermore, risk-tailored therapy is now possible, by cytogenetic risk stratification, promptness of remission induction, and identification of distinct clinical subgroups such as children with Down syndrome. This approach is rapidly changing potential therapeutic strategies for children with AML. It is in this changing mileu that we address the proper role of stem-cell transplantation, a modality that is changing (like chemotherapy) with expanding stem-cell sources and approaches to decrease transplant-related toxicity.

show abstract

Section: Future Directionsmentioning

confidence: 99%

Therapy for childhood acute myeloid leukemia: Role of allogeneic bone marrow transplantation

Abella

Ravindranath

2000

Curr Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Although allogeneic hematopoietic progenitor cell transplant (HPCT) is curative therapy for many disorders of lymphohematopoiesis, it is associated with significant morbidity and mortality 1–5. Much of this risk can be traced to graft-versus-host disease (GVHD) and the immunosuppressive measures required for its prevention and/or treatment 6,7.…”

Section: Introductionmentioning

confidence: 99%

Antiviral Responses following L-Leucyl-L-Leucine Methyl Esther (LLME)-Treated Lymphocyte Infusions: Graft-versus-Infection without Graft-versus-Host Disease

Filicko-O'Hara

Grosso

Flomenberg

et al. 2009

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

Although allogeneic hematopoietic progenitor cell transplant (HPCT) is curative therapy for many disorders, it is associated with significant morbidity and mortality, which can be related to graft-versus-host disease (GVHD) and the immunosuppressive measures required for its prevention and/or treatment. Whether the immunosuppression is pharmacologic or secondary to graft manipulation, the graft recipient is left at increased risk of the threatening opportunistic infection. Refractory viral diseases in the immunocompromised host have been treated by infusion of virus-specific lymphotyces and by unmanipulated donor lymphocyte infusion (DLI) therapy. L-leucyl-L-leucine methyl ester (LLME) is a compound that induces programmed cell death of natural killer (NK) cells, monocytes, granulocytes, most CD8(+) T cells, and a small fraction of CD4(+) T cells. We have undertaken a study of the use of LLME-treated DLI following T cell-depleted allogeneic HPCT, specifically to aid with immune reconstitution. In this ongoing clinical trial, we have demonstrated the rapid emergence of virus-specific responses following LLME DLI with minimal associated GVHD. This paper examines the pace of immune recovery and the rapid development of antiviral responses in 6 patients who developed viral infections during the time period immediately preceding or coincident with the administration of the LLME DLI.

show abstract

Mobilization of Allogeneic Peripheral Blood Progenitor Cells

Law¹,

Lane²

2002

Non-Myeloablative Allogeneic Transplantation

View full text Add to dashboard Cite

Use of nonmyeloablative preparative regimens for allogeneic blood stem cell transplantation: Induction of graft-vs.-malignancy as treatment for malignant diseases

Cited by 7 publications

References 56 publications

Therapy for childhood acute myeloid leukemia: Role of allogeneic bone marrow transplantation

Therapy for childhood acute myeloid leukemia: Role of allogeneic bone marrow transplantation

Antiviral Responses following L-Leucyl-L-Leucine Methyl Esther (LLME)-Treated Lymphocyte Infusions: Graft-versus-Infection without Graft-versus-Host Disease

Mobilization of Allogeneic Peripheral Blood Progenitor Cells

Contact Info

Product

Resources

About